Equities research analysts predict that Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) will report $0.08 earnings per share for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Amphastar Pharmaceuticals’ earnings. The highest EPS estimate is $0.11 and the lowest is $0.03. Amphastar Pharmaceuticals posted earnings of $0.12 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 33.3%. The company is expected to announce its next earnings report on Thursday, November 14th.

On average, analysts expect that Amphastar Pharmaceuticals will report full-year earnings of $0.30 per share for the current year, with EPS estimates ranging from $0.19 to $0.41. For the next financial year, analysts forecast that the company will report earnings of $0.92 per share, with EPS estimates ranging from $0.63 to $1.38. Zacks Investment Research’s EPS averages are an average based on a survey of research firms that that provide coverage for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its earnings results on Wednesday, August 7th. The company reported $0.08 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.05. The firm had revenue of $79.00 million for the quarter, compared to analysts’ expectations of $78.90 million. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. The business’s revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the business earned $0.03 earnings per share.

Several equities analysts have recently weighed in on the company. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $23.00 target price on the stock in a research report on Wednesday, July 10th. BidaskClub downgraded Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Co set a $29.00 price objective on Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, June 6th. Finally, TheStreet raised Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $24.64.

Shares of NASDAQ AMPH traded down $0.57 during trading hours on Monday, hitting $21.58. 7,195 shares of the company traded hands, compared to its average volume of 194,327. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of 102.62 and a beta of 1.17. The company has a current ratio of 2.81, a quick ratio of 1.83 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average price is $21.12 and its 200 day moving average price is $21.15. Amphastar Pharmaceuticals has a 12 month low of $17.71 and a 12 month high of $25.43.

In other news, SVP Yakob Liawatidewi sold 5,000 shares of the stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $20.73, for a total value of $103,650.00. Following the transaction, the senior vice president now directly owns 47,188 shares of the company’s stock, valued at $978,207.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard K. Prins sold 7,500 shares of the stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $22.59, for a total value of $169,425.00. Following the completion of the transaction, the director now directly owns 43,191 shares in the company, valued at $975,684.69. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,454 shares of company stock valued at $838,842. 30.80% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. Atria Investments LLC acquired a new stake in Amphastar Pharmaceuticals in the second quarter valued at approximately $449,000. United Services Automobile Association increased its stake in shares of Amphastar Pharmaceuticals by 55.2% during the second quarter. United Services Automobile Association now owns 15,207 shares of the company’s stock valued at $321,000 after acquiring an additional 5,409 shares during the period. Nuveen Asset Management LLC acquired a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at approximately $12,134,000. Citadel Advisors LLC increased its stake in shares of Amphastar Pharmaceuticals by 129.5% during the second quarter. Citadel Advisors LLC now owns 57,286 shares of the company’s stock valued at $1,209,000 after acquiring an additional 32,326 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new position in Amphastar Pharmaceuticals in the second quarter worth approximately $684,000. 47.26% of the stock is currently owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Read More: Compound Interest

Get a free copy of the Zacks research report on Amphastar Pharmaceuticals (AMPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.